MEDI-573 + aromatase inhibitor

MEDI-573 + aromatase inhibitor is a **combination therapy** under clinical investigation for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. MEDI-573 is a dual-targeting human monoclonal antibody that neutralizes insulin-like growth factor I (IGF-I) and IGF-II ligands, inhibiting downstream signaling through both insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor-A (IR-A), which are implicated in tumor growth and survival[2][3][5]. Aromatase inhibitors (AIs) are small-molecule drugs that inhibit the aromatase enzyme responsible for estrogen synthesis, thereby reducing estrogen levels and suppressing estrogen-dependent tumor proliferation[1][5]. The combination targets both estrogen synthesis and IGF signaling pathways, aiming for synergistic antitumor effects and overcoming resistance mechanisms in breast cancer therapy[2][3][5]. MEDI-573 is developed by AstraZeneca.

Other names

MEDI-573 with aromatase inhibitorMEDI573 with aromatase inhibitorMEDI 573 with aromatase inhibitorMEDI-573 + AI